The Systemic Cytokine Environment Is Permanently Altered in Multiple Myeloma

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Zheng, Mary M ^a   Zhang, Zhifang ^b   Bemis, Kyle ^a   Belch, Andrew R ^c   Pilarski, Linda M ^c   Shively, John E ^b   Kirshner, Julia ^a  

^a PURDUE UNIVERSITY   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CXCL9 CHEMOKINE; EOTAXIN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; SOLUBLE INTERLEUKIN 2 RECEPTOR; TRANSFORMING GROWTH FACTOR BETA2; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CARCINOGENESIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMORAL IMMUNITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN HOMEOSTASIS; TUMOR MICROENVIRONMENT;

ADULT; AGED; AGED, 80 AND OVER; AGING; CASE-CONTROL STUDIES; COMPLEMENT SYSTEM PROTEINS; CYTOKINES; DISCRIMINANT ANALYSIS; FEMALE; HOMEOSTASIS; HUMANS; IMMUNITY, HUMORAL; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; PHENOTYPE; REMISSION INDUCTION; SEX CHARACTERISTICS; YOUNG ADULT;

EID: 84875442342     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058504     Document Type: Article

References (45)

1. Fulop T, Larbi A, Witkowski JM, McElhaney J, Loeb M, et al. (2010) Aging, frailty and age-related diseases. Biogerontology 11: 547-563.
2. Kirkwood TB, (2005) Understanding the odd science of aging. Cell 120: 437-447.
3. Busse PJ, Mathur SK (2010) Age-related changes in immune function: effect on airway inflammation. J Allergy Clin Immunol 126: 690-699; quiz 700-691.
4. Franceschi C, Capri M, Monti D, Giunta S, Olivieri F, et al. (2007) Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev 128: 92-105.
5. Forsey RJ, Thompson JM, Ernerudh J, Hurst TL, Strindhall J, et al. (2003) Plasma cytokine profiles in elderly humans. Mech Ageing Dev 124: 487-493.
6. Riancho JA, Zarrabeitia MT, Amado JA, Olmos JM, Gonzalez-Macias J, (1994) Age-related differences in cytokine secretion. Gerontology 40: 8-12.
7. Morley JE, Baumgartner RN, (2004) Cytokine-related aging process. J Gerontol A Biol Sci Med Sci 59: M924-929.
8. Gangemi S, Basile G, Monti D, Merendino RA, Di Pasquale G, et al. (2005) Age-related modifications in circulating IL-15 levels in humans. Mediators Inflamm 2005: 245-247.
9. Chipeta J, Komada Y, Zhang XL, Deguchi T, Sugiyama K, et al. (1998) CD4+ and CD8+ cell cytokine profiles in neonates, older children, and adults: increasing T helper type 1 and T cytotoxic type 1 cell populations with age. Cell Immunol 183: 149-156.
10. Ouyang X, Yang Z, Zhang R, Arnaboldi P, Lu G, et al. (2011) Potentiation of Th17 cytokines in aging process contributes to the development of colitis. Cell Immunol 266: 208-217.
11. Sartono E, Kruize YC, Kurniawan A, Maizels RM, Yazdanbakhsh M, (1997) Depression of antigen-specific interleukin-5 and interferon-gamma responses in human lymphatic filariasis as a function of clinical status and age. J Infect Dis 175: 1276-1280.
12. Fulop T, Larbi A, Kotb R, de Angelis F, Pawelec G, (2011) Aging, immunity, and cancer. Discov Med 11: 537-550.
13. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, et al. (2007) Inflammation in prostate carcinogenesis. Nat Rev Cancer 7: 256-269.
14. Li Z, Jiang J, Wang Z, Zhang J, Xiao M, et al. (2008) Endogenous interleukin-4 promotes tumor development by increasing tumor cell resistance to apoptosis. Cancer Res 68: 8687-8694.
15. Bonafe M, Storci G, Franceschi C, (2012) Inflamm-aging of the stem cell niche: breast cancer as a paradigmatic example: breakdown of the multi-shell cytokine network fuels cancer in aged people. Bioessays 34: 40-49.
16. De Monte L, Reni M, Tassi E, Clavenna D, Papa I, et al. (2011) Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med 208: 469-478.
17. Nevala WK, Vachon CM, Leontovich AA, Scott CG, Thompson MA, et al. (2009) Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma. Clin Cancer Res 15: 1931-1939.
18. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, et al. (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111: 2516-2520.
19. Palumbo A, Anderson K, (2011) Multiple myeloma. N Engl J Med 364: 1046-1060.
20. Kyle RA, Rajkumar SV, (2009) Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 23: 3-9.
21. Bataille R, Manolagas SC, Berenson JR, (1997) Pathogenesis and management of bone lesions in multiple myeloma. Hematol Oncol Clin North Am 11: 349-361.
22. Kowalska M, Kaminska J, Fuksiewicz M, Kotowicz B, Chechlinska M, et al. (2011) A survey of prognostic value of serum factors in multiple myeloma patients before treatment: macrophage-colony stimulating factor (M-CSF) is a powerful predictor of survival. Med Oncol 28: 194-198.
23. Kroning H, Tager M, Thiel U, Ittenson A, Reinhold D, et al. (1997) Overproduction of IL-7, IL-10 and TGF-beta 1 in multiple myeloma. Acta Haematol 98: 116-118.
24. Frassanito MA, Cusmai A, Dammacco F, (2001) Deregulated cytokine network and defective Th1 immune response in multiple myeloma. Clin Exp Immunol 125: 190-197.
25. Klein B, Bataille R, (1992) Cytokine network in human multiple myeloma. Hematol Oncol Clin North Am 6: 273-284.
26. Tinhofer I, Marschitz I, Henn T, Egle A, Greil R, (2000) Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. Blood 95: 610-618.
27. Lu ZY, Bataille R, Poubelle P, Rapp MJ, Harousseau JL, et al. (1995) An interleukin 1 receptor antagonist blocks the IL-1-induced IL-6 paracrine production through a prostaglandin E2-related mechanism in multiple myeloma. Stem Cells 13 (Suppl 2): 28-34.
28. Nucci M, Anaissie E, (2009) Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis 49: 1211-1225.
29. Chang DH, Osman K, Connolly J, Kukreja A, Krasovsky J, et al. (2005) Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med 201: 1503-1517.
30. Kirshner J, Thulien KJ, Martin LD, Debes Marun C, Reiman T, et al. (2008) A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma. Blood 112: 2935-2945.
31. Smyth GK (2005) Limma: linear models for microarray data. Bioinformatics and Computational Biology Solutions using R and Bioconductor: 397-420.
32. Bikker A, Moret FM, Kruize AA, Bijlsma JW, Lafeber FP, et al. (2012) IL-7 drives Th1 and Th17 cytokine production in patients with primary SS despite an increase in CD4 T cells lacking the IL-7Ralpha. Rheumatology (Oxford) 51: 996-1005.
33. Gonda TA, Tu S, Wang TC, (2009) Chronic inflammation, the tumor microenvironment and carcinogenesis. Cell Cycle 8: 2005-2013.
34. Liva SM, Voskuhl RR, (2001) Testosterone acts directly on CD4+ T lymphocytes to increase IL-10 production. J Immunol 167: 2060-2067.
35. Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, et al. (2004) The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab 89: 3313-3318.
36. Grivennikov SI, Greten FR, Karin M, (2010) Immunity, inflammation, and cancer. Cell 140: 883-899.
37. Yu WG, Yamamoto N, Takenaka H, Mu J, Tai XG, et al. (1996) Molecular mechanisms underlying IFN-gamma-mediated tumor growth inhibition induced during tumor immunotherapy with rIL-12. Int Immunol 8: 855-865.
38. Salazar-Onfray F, (1999) Interleukin-10: a cytokine used by tumors to escape immunosurveillance. Med Oncol 16: 86-94.
39. Nitsche A, Junghahn I, Thulke S, Aumann J, Radonic A, et al. (2003) Interleukin-3 promotes proliferation and differentiation of human hematopoietic stem cells but reduces their repopulation potential in NOD/SCID mice. Stem Cells 21: 236-244.
40. Kruger C, Laage R, Pitzer C, Schabitz WR, Schneider A, (2007) The hematopoietic factor GM-CSF (granulocyte-macrophage colony-stimulating factor) promotes neuronal differentiation of adult neural stem cells in vitro. BMC Neurosci 8: 88.
41. Kikuchi K, Kasai H, Watanabe A, Lai AY, Kondo M, (2008) IL-7 specifies B cell fate at the common lymphoid progenitor to pre-proB transition stage by maintaining early B cell factor expression. J Immunol 181: 383-392.
42. Matsui W, Borrello I, Mitsiades C, (2012) Autologous stem cell transplantation and multiple myeloma cancer stem cells. Biol Blood Marrow Transplant 18: S27-32.
43. Corfe SA, Paige CJ, (2012) The many roles of IL-7 in B cell development; mediator of survival, proliferation and differentiation. Semin Immunol 24: 198-208.
44. Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J, Carreras L, Arranz EA, et al. (2007) Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A 104: 240-245.
45. Zhang XL, Zhang WH, Fan XH, Wei F, Zhang M, (2012) [Serum Level of IL-17 in Patients with Multiple Myeloma and Its Clinical Significance]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 20: 930-932.